Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical therapy is recommended among patients with metastatic disease: | |||
* Chemotherapy | |||
** Dacarbazine | |||
** Temozolomide | |||
** Cisplatin | |||
** Treosulfan | |||
** Fotemustine | |||
* Immunotherapy | |||
** Checkpoint blockade | |||
*** Pembrolizumab | |||
*** Ipilimumab + nivolumab | |||
*** Ipilimumab + nivolumab | |||
*** Ipilimumab + radioembolization | |||
*** Ipilimumab + nivolumab +radioembolization | |||
** TILs | |||
** T cell redirection | |||
** Antibody–drug conjugate | |||
*** Glembatumumab vedotin | |||
* Targeted therapy | |||
** PKC/MEK | |||
*** AEB071 + BYL719 | |||
*** Intermittent selumetinib | |||
*** Selumetinib +/– paclitaxel | |||
*** Binimetinib + AEB071 | |||
** Multikinase inhibition | |||
*** Sorafenib (STREAM) | |||
*** Cabozantinib versus temozolomide/ dacarbazine | |||
** Epigenetic therapy | |||
*** HDAC inhibition | |||
**** Vorinostat | |||
**** Pembrolizumab + entinostat (PEMDAC) | |||
*** BET inhibition | |||
** Liver-directed therapy | |||
*** IHP | |||
*** PHP <br /> | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 03:10, 16 August 2019
Uveal melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Uveal melanoma medical therapy On the Web |
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:
- Chemotherapy
- Dacarbazine
- Temozolomide
- Cisplatin
- Treosulfan
- Fotemustine
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC/MEK
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multikinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET inhibition
- HDAC inhibition
- Liver-directed therapy
- IHP
- PHP
- PKC/MEK